Lung-on-a-chip: the future of respiratory disease models and pharmacological studies
- Publication Type:
- Journal Article
- Citation:
- Critical Reviews in Biotechnology, 2020, 40 (2), pp. 213 - 230
- Issue Date:
- 2020-02-17
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
MED319067 am.pdf | Accepted Manuscript Version | 3.78 MB | |||
MED319067 published.pdf | 3.83 MB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Recently, organ-on-a-chip models, which are microfluidic devices that mimic the cellular architecture and physiological environment of an organ, have been developed and extensively investigated. The chips can be tailored to accommodate the disease conditions pertaining to many organs; and in the case of this review, the lung. Lung-on-a-chip models result in a more accurate reflection compared to conventional in vitro models. Pharmaceutical drug testing methods traditionally use animal models in order to evaluate pharmacological and toxicological responses to a new agent. However, these responses do not directly reflect human physiological responses. In this review, current and future applications of the lung-on-a-chip in the respiratory system will be discussed. Furthermore, the limitations of current conventional in vitro models used for respiratory disease modeling and drug development will be addressed. Highlights of additional translational aspects of the lung-on-a-chip will be discussed in order to demonstrate the importance of this subject for medical research.
Please use this identifier to cite or link to this item: